Arcitumomab
As of the edition of 20 October 2026, Arcitumomab is an antibody: marketed, first approved in 2007 (JP); acts on CEACAM5.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2007
- Kind
- Antibody
- First approved
- 4 April 2007 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Kirin Brewery
- Withdrawn from market
- 27 September 2005 (in some regions)
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CEACAM5 | Cell adhesion molecule CEACAM5 | P06731 |